Prospective Cohort Study With Central Nervous System Evaluation in Diffuse Large B-cell Lymphoma

N/ACompletedNCT01202448

Samsung Medical Center600 enrolled

Overview

This study is to evaluate the incidence of central nervous system (CNS) relapse or metastasis in patients with diffuse large B-cell lymphoma.

We dichotomize patients according to the risk of CNS involvement. Then, we perform CNS evaluation in patients at risk of CNS involvement. We prospectively monitor whether CNS relapse or metastasis occurs in patients with diffuse large B-cell lymphoma

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

DIAGNOSTIC

Masking

NONE

Enrollment

600

Conditions

Diffuse Large B-cell Lymphoma

Interventions

CSF analysisPROCEDURE

The cerebrospinal fluid will be evaluated via lumbar puncture.

Eligibility

Sex: ALLMin age: 20 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. Newly diagnosed patients with diffuse large B cell lymphoma 2. \> 20 years 3. life expectancy more than 6 months 4. Written informed consent Exclusion Criteria: 1. Refusal to informed consent 2. Lymphomas other than diffuse large B cell lymphoma 3. Primary CNS lymphoma

Locations (2)

Samsung Medical Center

Seoul, South Korea

Asan Medical Center

Seoul, South Korea

Outcomes

Primary Outcomes

CNS relapse/involvement

After enrollment, patients will be monitored to check the CNS relapse or involvement

Time frame: Up to 2 years after participants are enrolled.

Secondary Outcomes

survival

The survival outcome of patients will be monitored.

Time frame: Up to 2 years after participants are enrolled

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.